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Abstract
Background: The impact of autoimmune diseases on pregnancy remains understudied on a
population level. Examination of obstetric and neonatal outcomes among women with
autoimmune disease and their infants can provide important insights for clinical management.
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Methods: Autoimmune diseases and outcomes were identified using medical records. Cesarean
delivery, preterm birth, preeclampsia, small for gestational age (SGA), neonatal intensive care
(NICU) admission, neonatal respiratory distress syndrome (RDS), and perinatal mortality risk was
assessed. Poisson regression with robust standard errors estimated relative risks (RR) and 95%
confidence intervals (95% CI) with adjustment for maternal characteristics and other chronic
conditions.
Results: Women with T1DM were at increased risk for nearly all outcomes including RDS (RR:
3.62; 95% CI: 2.84, 4.62), perinatal mortality (RR: 2.35; 95% CI: 1.12, 4.91), cesarean delivery
(RR: 2.16; 95% CI: 2.02, 2.32) and preterm birth (RR: 3.52; 95% CI: 3.17, 3.91). Women with
SLE also had higher risk for preterm delivery (RR: 2.90; 95% CI: 2.42, 3.48) and RDS (RR:2.99;
95% CI: 1.99, 4.51) as did women with Crohn’s (cesarean delivery RR:1.31, 95% CI: 1.08, 1.60;
preterm delivery RR: 1.84, 95% CI: 1.37, 2.49. RA increased risk for SGA (RR:1.66; 95% CI:
1.08, 2.55).

Author Manuscript

Conclusion(s): Despite the heterogeneity in autoimmune diseases, we observed elevated
preterm birth risk for most women with autoimmune disease. SLE and T1DM appeared to confer
increased risk for a wide range of adverse outcomes.
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1.

Introduction
The worldwide estimated cumulative prevalence of autoimmune disease is approximately
5% [1], and increasing [2]. Approximately 66% of autoimmune diseases have a mean age of
onset less than 50 years [1], and 80% of autoimmune cases in the U.S. occur among women
[3,4]. It is important to understand the effect autoimmune diseases have on pregnant women
and their infants.
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The physiologic regulation of inflammation during pregnancy plays an important function in
obstetric and neonatal outcomes. Inflammation, an immune-mediated response, assists in
implantation and placentation early in pregnancy. Inflammation also promotes parturition
and placental expulsion [5]. Later in gestation, pro-inflammatory processes at the maternal/
fetal interface due to infection or placental abruption may lead to preterm birth,
preeclampsia, and other adverse outcomes [6]. Research into the etiology of these outcomes
is warranted. Inflammation is a key feature of autoimmune disease [3,4,7]. However, the
population-level impact of autoimmune diseases on pregnancy remains understudied. Our
previous work found women with asthma or thyroid disease had an increased risk for poor
obstetric and infant outcomes [8–10], yet not all cases of asthma or thyroid disease are
autoimmune. The underlying biologic mechanisms linking autoimmune disease and
increased risk of adverse obstetric and neonatal outcomes are not well understood yet may
result from overlapping physiologic adaptations necessary for pregnancy [11,12], their
disease states [13–20], the presence of autoantibodies or medications [21,22] required for
management during pregnancy [17,21,23,24].
A challenge in studying the association of autoimmune diseases with obstetric and neonatal
outcomes is the rarity of both. Research conducted to date is largely among homogenous
populations outside the U.S. [14–17,22,25–41]. Studies conducted among U.S. populations
are often limited by small sample sizes [21,30,40] or focused on a specific autoimmune
disease and lacked detailed data on multiple obstetric and infant outcomes [34,42,43].
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Cesarean delivery and preterm delivery are most frequently examined in the existing
literature. Women with type 1 diabetes mellitus (T1DM) [12,32,41,44], systemic lupus
erythematosus (SLE) [45–48], Crohn’s disease [49–52] or rheumatoid arthritis (RA)
[22,53,54] are reported to be at increased risk for cesarean delivery but evidence among
women with multiple sclerosis (MS) is mixed. Two population-based studies found women
with MS had approximately 40% higher risk for cesarean delivery [27,28], while two other
population-based studies [26,55] and two small case-control studies [25,56] found no
increased risk. In addition, prior studies did not explore the indications or timing of cesarean
deliveries (prelabor or intrapartum).
Similarly, evidence among women with T1DM [14,44], SLE [18,57], Crohn’s [52,58,59] or
RA [18,31,34] suggests increased risk of preterm birth while reports of preterm birth risk
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among women with MS are inconsistent. Two population-based studies report an increased
preterm birth risk among women with MS [27,28], and four other studies report no increased
risk [25,26,29,30]. No data are available regarding precursors of preterm birth or
spontaneous versus induced deliveries among women with autoimmune disease.
Evidence for other prevalent complications associated with autoimmune disease is also
inconclusive. For example, among women with RA, four studies report an increased risk of
small for gestational age (SGA) [21,31,32,60], while four studies report no increased risk of
SGA [16,22,33,34]. Evidence regarding neonatal intensive care unit (NICU) admission is
also sparse with mixed results [15–17,22,33,35–40]. For certain autoimmune diseases like
T1DM, and Crohn’s disease, studies are limited and none have been conducted among US
populations [14,15,39,41].
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Using a nationwide US cohort, we aimed to provide a more comprehensive description of
the obstetric and neonatal risks among women with autoimmune disease and their infants.
To better understand obstetric and neonatal risks associated with maternal autoimmune
disease, we examined women in the Consortium on Safe Labor (CSL) diagnosed with
T1DM, SLE, Crohn’s, MS, or RA. These diseases are heterogeneous and their target tissues
vary (pancreatic β-cells for T1DM [61]; various tissues including musculoskeletal, renal,
and central nervous system for SLE [62]; bowel in Crohn’s [63]; the nervous system in MS
[64]; and musculoskeletal system in RA [65]).

2.
2.1.

Materials and methods
Consortium on Safe Labor
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The CSL was a U.S. retrospective cohort study from 2002 to 2008 that abstracted labor and
delivery information from electronic medical records from 19 U.S. hospitals. Data extracted
for deliveries at 23 gestational weeks or later (n = 228,438) included: maternal sociodemographic characteristics, medical, reproductive and prenatal history, labor and delivery
summaries, postpartum and newborn data [66]. For these analyses, we excluded multifetal
pregnancies (n = 5,063, 2.2%), mothers with thyroid disease (n = 3,772, 1.6%), mothers with
other autoimmune disease (n = 1,764, 0.7%) such as unspecified diseases of connective
tissue, thrombophilia, hemorrhagic conditions, ulcerative colitis, coeliac disease, Grave’s
disease and Hashimoto’s thyroiditis, and participants from one site for which ICD-9 codes
were not reported and no cases of the autoimmune diseases of interest were identified (n =
12,318, 5.3%). Our final analytic sample included 205,521 deliveries. Institutional Review
Boards approval was obtained at all participating sites and data are de-identified.
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2.2.

Autoimmune diseases of interest
Relatively common maternal autoimmune diseases were selected for analyses in part to
ensure sufficient sample size. T1DM, SLE, Crohn’s, MS, and RA were identified using
delivery admission electronic medical records and discharge ICD-9 codes (Supplementary
Table 1). The sensitivity of these codes for obstetric conditions is generally good [66–68].
For women with multiple pregnancies during the study period, a diagnosis of autoimmune
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disease was assumed for subsequent pregnancies (52 repeat pregnancies among women with
autoimmune disease, 4.5% of pregnancies to women with autoimmune disease).
2.3.

Obstetric and neonatal outcomes
Outcome variables were elected based on prevalence and prior studies: cesarean delivery
(overall, pre-labor, after induced labor, and after spontaneous labor), preeclampsia, preterm
birth (< 37 weeks of gestation; overall, spontaneous preterm delivery, indicated preterm
delivery), small for gestational age, NICU admission, neonatal respiratory distress syndrome
(RDS), and perinatal mortality (pregnancy loss ≥ 23 weeks of gestation through neonatal
mortality ≤ 7 days) were identified from maternal and neonatal medical records
supplemented with discharge ICD-9 codes (Supplementary Table 1).

2.4.

Statistical analysis
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Descriptive statistics were summarized by autoimmune disease status (Present/Absent).
Binary Poisson regression models with the log link function and robust standard errors to
account for repeat pregnancies estimated relative risks (RR) and 95% confidence intervals
(95% CI) for the association between autoimmune disease and out-comes of interest.
Women with autoimmune disease and their infants were compared to women without any
autoimmune disease. Models were adjusted for maternal age (continuous), maternal race/
ethnicity (White, Black, Hispanic, Asian/Pacific Islander, Other), health insurance (public,
private, other), marital status (married, divorced/widowed, single, unknown), smoking
during pregnancy (yes/no), alcohol use during pregnancy (yes/no), any other chronic
diseases (yes/no: type 2 diabetes, asthma, depression, heart disease, hypertension, renal
disease) and census region (Northeast, West, South, Midwest), based on previous literature
[4,20,22,27,31,41,48,52].
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We also compared indications for cesarean delivery and precursors for preterm delivery by
autoimmune disease status. All statistical analyses were conducted using SAS 9.4 (SAS
Institute Inc., Cary, NC, USA). We did not adjust for multiple comparisons [69].

3.
3.1.

Results
Prevalence of autoimmune diseases
The prevalence of autoimmune diseases (cases per 1000 pregnancies) for the CSL
population by demographic variables are presented in Table 1.
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Black women had the highest rates of T1DM (2.9/1000) and SLE (1.3/1000), while white
women had the highest rates of Crohn’s (1.4/ 1000), MS (1/1000), and RA (0.8/1000).
Women with private insurance had the highest rates of SLE (1.1/1000), Crohn’s (1.1/1000),
and MS (0.9/1000). Women with public insurance had the highest rate of T1DM (2.9/1000).
Rates of T1DM, SLE, and Crohn’s varied by census region. Rates of T1DM were highest for
women in the Midwest (3.1/1000) and the South (2.9/1000). Women in the South had the
highest rate of SLE (1.4/1000), and women in the Northeast had the highest rate of Crohn’s
disease (1.4/1000).
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Women with autoimmune disease and their infants generally experienced more adverse
outcomes compared to women without autoimmune disease (Tables 2 and 3). Women with
any of the examined autoimmune diseases, when compared to women without autoimmune
disease, had significantly higher rates of cesarean delivery, pre-labor cesarean delivery,
preterm birth, and spontaneous preterm birth. Women with T1DM, SLE, or Crohn’s also had
higher rates of preeclampsia and indicated preterm birth. Women with T1DM or SLE had
similarly high rates of poor obstetric outcomes, except for cesarean delivery, where T1DM
was associated with the highest rates (Table 2).
Only women with SLE or RA had significantly higher rates of SGA, while women with
T1DM had lower rates of SGA as expected, compared to women without autoimmune
disease.
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3.2.

Risk of adverse obstetric and neonatal outcomes
Results were similar in adjusted analyses (Table 3), with all autoimmune diseases associated
with increased risk for cesarean delivery, including for pre-labor cesarean and cesarean after
induced or spontaneous labor, and preterm birth, including both indicated and spontaneous
preterm birth.
Models adjusted for maternal age, maternal race/ethnicity, preconception body mass index,
health insurance, marital status, smoking in pregnancy, alcohol use in pregnancy, other
chronic diseases, and census region.; *p < 0.05 indicates rates among women with
autoimmune disease different than rates among women without autoimmune disease.
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Women with T1DM were at increased risk for most poor obstetric outcomes, except for
SGA (RR:0.61, 95% CI: 0.43, 0.86). Similarly, women with SLE were at increased risk for
most obstetric outcomes.
Infants born to women with autoimmune disease, compared to those born to women without
autoimmune disease, appear to have elevated risk for most adverse neonatal outcomes, but
many associations did not reach statistical significance (Tables 2 and 3). However, compared
to infants born to women without autoimmune disease, infants born to women with T1DM
were three times more likely to experience RDS (RR: 3.62; 95% CI: 2.84, 4.62), and twice
as likely to experience perinatal mortality (RR: 2.35; 95% CI: 1.12, 4.91), and had a 25%
risk of NICU admission (RR: 1.25; 95% CI: 1.16, 1.35). Infants born to women with SLE
had similar increases in risk for RDS and NICU admission.
3.3.

Intrapartum cesarean delivery and indicated preterm delivery

Author Manuscript

As risk of cesarean or preterm delivery were increased for women with autoimmune
diseases, we examined indications for intrapartum cesarean deliveries (Table 4) and for
indicated preterm deliveries (Table 5).
For intrapartum cesarean deliveries (Table 4), failure to progress was the most common
indication for women with T1DM, Crohn’s, MS or RA. Among women with T1DM,
Crohn’s or MS, rate of failure to progress was significantly higher than among women
without autoimmune disease. Among women with SLE, non-reassuring fetal heart rate
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tracing was the most common indication and was nearly three-fold higher than among
women without autoimmune disease. Compared to women without autoimmune disease,
women with T1DM, SLE, Crohn’s or RA had three-to five-fold higher rates of hypertensive
disorders as indication for intrapartum cesarean delivery. Women with T1DM had the
greatest number of significantly higher rates of indications, including prior uterine scar
(90.7/1000), fetal distress (78.9/1000) and elective (47.3/1000).
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For indicated preterm deliveries (Table 5), rates of preeclampsia, superimposed
preeclampsia, and maternal conditions were higher among women with T1DM, SLE,
Crohn’s or MS compared to women without autoimmune disease. Women with T1DM had
significantly higher rates for nine indications, including chronic hypertension (15.77/1000),
fetal anomaly (27.6/1000), fetal macrosomia (1.97/1000), and history of previous pregnancy
condition (27.61/1000). Women with SLE had statistically significant higher rates for six
indications, including chorioamnionitis (4.95/1000), fetal anomaly (24.75/1000), and other
fetal conditions (14.8/1000).

4.

Discussion

Author Manuscript

Despite advances in management of autoimmune disease that aid women in fulfilling family
plans, pregnant women with autoimmune diseases continue to experience increased risk of
poor obstetric and neonatal outcomes. We found the risk for cesarean delivery after
spontaneous or induced labor was similar among women with T1DM. However, the
increased risk of overall cesarean delivery for women with SLE, Crohn’s, MS or RA may
have been due to increased risk of cesarean delivery after spontaneous labor. The increased
risk of preterm delivery may be driven by indicated preterm deliveries among women with
T1DM or SLE, but both indicated and spontaneous preterm delivery risk were elevated for
women with Crohn’s, MS or RA.
The richness of the CSL data allowed us to examine indications for cesarean delivery and
preterm delivery. Despite heterogeneity of symptoms across types of autoimmune disease,
failure to progress, nonreassuring fetal heart rate tracing, and maternal hypertensive
disorders were common indications for intrapartum cesarean section across types of
autoimmune disease, with evidence particularly strong among women with T1DM (Table 4).
Preeclampsia and maternal comorbidities were more likely to be indicators for preterm
delivery among women with autoimmune diseases compared to women without autoimmune
disease (Table 5). Examining these indications can provide clinicians with new information
on risk factors for poor obstetric outcomes among women with autoimmune disease.
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These observations among women with a heterogenous set of autoimmune diseases
underscores the importance of immunologic health during pregnancy, and the importance of
a mother’s immunologic health for her neonate. For instance, women with T1DM or SLE
had similarly increased risk for a range of adverse obstetric and neonatal outcomes, despite
heterogenous symptoms and different target tissues. The observations among women with
T1DM or SLE align with previous evidence regarding cesarean delivery, preterm delivery,
and small for gestational age births [12,14,17,18,32,41,44–48,57]. We provide the first
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evidence among a U.S. cohort that infants born to women with T1DM or SLE were at
increased risk for RDS and NICU admission.
Obstetric risks for women with MS or RA have been underexamined in extant literature. Our
observation of increased preterm delivery risk among women with MS suggests this
association merits further attention. We also add evidence suggesting an increased risk of
SGA births among women with RA.
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The results which were not statistically significant still provide interesting details regarding
obstetric and neonatal risks among women with autoimmune disease. For example, the risk
estimates for cesarean delivery after spontaneous labor suggest increased risk among women
with SLE, Crohn’s, MS or RA, but with a lack of statistical power. Similarly, results suggest
infants of women with Crohn’s may be at increased risk for SGA and RDS, and women with
RA may be at increased risk for cesarean delivery overall and after spontaneous labor, at
increased risk for overall and indicated preterm delivery, and RDS, although estimates were
imprecise. Additionally, the differences in magnitude of effects observed across autoimmune
diseases and obstetric outcomes are notable. For example, the risk for cesarean delivery after
induced labor among women with SLE, Crohn’s, MS or RA is close to null. These results
differ from the 250% increased risk for cesarean delivery after induced labor among women
with T1DM, suggesting the risk of poor outcomes is not uniform across autoimmune
diseases.
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This study has several notable strengths. This is the first study of a large, U.S.-based cohort
of pregnant women with a heterogeneous group of autoimmune diseases that assessed
multiple obstetric and neonatal outcomes. While the CSL is not a nationally representative
sample, the CSL is geographically varied, racially/ethnically diverse and includes women
across the reproductive age range, it is a good representation of the pregnancy outcomes
among women with autoimmune diseases in the U.S. To the best of our knowledge, this is
the first study to examine a large, U.S.-based cohort in which women with T1DM are
compared to general population controls. Additionally, we provide the first evidence of
NICU admission risk among the infants of women with a variety of autoimmune diseases.
We also provide novel evidence that infants born to women with SLE and T1DM are at
increased risk for RDS. The neonatal risks observed are not only important in the short-term,
but also can impact the health of these children as they age [70,71]. Cohort studies enriched
with children born to mothers with autoimmune disease may be required to fully explore
these risks due to the rarity of autoimmunity in pregnancy.
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Our novel observations fill existing knowledge gaps that can inform clinicians counseling
women with autoimmune disease regarding their family plans. There are few resources for
clinicians that evaluate common autoimmune disorders and identify the obstetric and
neonatal risks for women who are affected. This information allows women with
autoimmune disease to make better informed decisions regarding their reproductive health in
consultation with their physicians.
The retrospective cross-sectional design of the CSL limited our ability to consider two
important aspects of autoimmune disease. First, we do not have data on diagnosis date to
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determine the length of time with disease prior to pregnancy. Evidence suggests women who
have had an autoimmune disease for a longer period of time have worse health outcomes
compared to women who have had the same autoimmune disease for a shorter period of time
[72]. Secondly, we do not have data regarding disease management and symptomology
during pregnancy. As autoimmune diseases are often managed on a daily basis, the disease
activity during pregnancy is known to be an important determinant of pregnancy outcomes.
Additionally, CSL data lacks medication use and biologic measures that would be helpful to
assess mechanisms linking autoimmune disease and pregnancy outcomes.
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Potential mechanisms linking maternal autoimmune disease with obstetric and neonatal
outcomes are not well understood. Longitudinal investigations of immunologic health of
pregnant women with autoimmune diseases are needed to better understand the general
physiology of autoimmune disease during pregnancy, and to understand how daily
management of these diseases, including disease flare ups, impacts pregnancy. While
advances in the treatment and management of autoimmune disease have aided women in
fulfilling their family plans, our data indicate that women with autoimmune disease may still
have high risk for adverse outcomes.
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Relying on the ICD-9 codes for autoimmune diagnoses may have missed several cases, but
we expect that these conditions would be recorded in the medical records since they are
likely to cause complications of pregnancy and are relevant for labor and delivery. Since the
delivery admission hospitalization record has limited data on maternal chronic disease, we
assume the reported risks of poor obstetric and neonatal outcomes among women with
autoimmune disease are average risks. We recognize that unmeasured factors such as disease
severity, length of time with disease, and management of disease may result in a risk profile
differing from our observations. Clinical researchers can build upon this foundation to better
understand how risk profiles may differ in order to provide better treatment options and
allow for more informed decision making among their patients.
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While we did not have treatment or disease severity data, recent recommendations suggest
women with autoimmune disease wishing to become pregnant should discuss treatment
options with their clinicians [73–79]. Preconception management may include altering
medication, as certain treatments for RA, Crohn’s and SLE are contraindicated with
pregnancy [74,75,77,78]. Management of preconception blood glucose levels may limit risk
of nephropathy among women with T1DM, and nephropathy has been suggested as a
potential mechanism for increased risk of preeclampsia among women with T1DM [73], and
poor glucose control during pregnancy and labor may increase risk for perinatal mortality
[80]. During pregnancy, standard course of care is typically recognized as safe for mother
and fetus, unless medications have been contraindicated for pregnancy [73–79]. Infants born
to women with autoimmune disease may require initial NICU admission or additional
examinations per hospital policy, thus clinicians and pregnant women with autoimmune
disease should discuss potential care plans covering the immediate postpartum period. For
example, women with T1DM should be aware that NICU admission, blood glucose testing,
blood lipids testing, and echocardiograms may be included as standard course of care for
their infants [79]. Furthermore, clinicians should closely monitor blood glucose levels of
women with T1DM during labor and delivery, and insulin drip during labor has been
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recommended to maintain blood glucose levels [80]. These findings of increased risk of
NICU admission and RDS among neonates suggest more attention to neonates of mothers
with autoimmune disease is warranted.
In conclusion, in this comprehensive examination of multiple autoimmune diseases and
various obstetric and neonatal outcomes in a national sample of U.S. women and their
infants, maternal autoimmune disease was associated with poor obstetric and infant
outcomes, especially preterm birth. These increased risks were observed despite the
heterogeneity of symptomology across various autoimmune diseases, highlighting the
importance of research to better understand immunologic function during pregnancy and to
better guide prenatal care and inform patient-provider decision making regarding pregnancy
for women with autoimmune disease.

Author Manuscript

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.

Acknowledgments
Source of funding
This research was supported by the Intramural Research Program of the National Institutes of Health, Eunice
Kennedy Shriver National Institute of Child Health and Human Development (NICHD), including funding for the
Consortium on Safe Labor (Contract No. HHSN267200603425C) and the Air Quality and Reproductive Health
Study (Contract No. HHSN275200800002I, Task Order No. HHSN27500008). This paper has been cleared for
publication by the NICHD but the funding source had no role in the design, analysis, interpretation or writing of the
manuscript.

Author Manuscript

References

Author Manuscript

[1]. Hayter SM, Cook MC, Updated assessment of the prevalence, spectrum and case definition of
autoimmune disease, Autoimmun. Rev. 11 (2012) 754–765. [PubMed: 22387972]
[2]. Lerner A, Jeremias P, Matthias T, The world incidence and prevalence of autoimmune diseases is
increasing, Int. J. Celiac Dis. 3 (2015) 151–155.
[3]. Jacobson DL, Gange SJ, Rose NR, Graham NM, Epidemiology and estimated population burden
of selected autoimmune diseases in the United States, Clin. Immunol. Immunopathol. 84 (1997)
223–243. [PubMed: 9281381]
[4]. Cooper GS, Stroehla BC, The epidemiology of autoimmune diseases, Autoimmun. Rev. 2 (2003)
119–125. [PubMed: 12848952]
[5]. Mor G, Cardenas I, Abrahams V, Guller S, Inflammation and pregnancy: the role of the immune
system at the implantation site, Ann. N. Y. Acad. Sci. 1221 (2011) 80–87. [PubMed: 21401634]
[6]. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF, Petraglia F, Inflammation and
pregnancy, Reprod. Sci. 16 (2009) 206–215. [PubMed: 19208789]
[7]. Mackay IR, Gershwin ME, The nature of autoimmune disease, Semin. Liver Dis. 17 (1997) 3–11.
[PubMed: 9089906]
[8]. Mendola P, Laughon SK, MÄNnistÖ TI, Leishear K, Reddy UM, Chen Z, et al., Obstetric
complications among US women with asthma, Am. J. Obstet. Gynecol. 208 (2013) 127 el-.e8.
[PubMed: 23159695]
[9]. Mendola P, Männistö TI, Leishear K, Reddy UM, Chen Z, Laughon SK, Neonatal health of infants
born to mothers with asthma, J. Allergy Clin. Immunol. 133 (2014), https://doi.Org/10.1016/
j.jaci.2013.06.012.

J Autoimmun. Author manuscript; available in PMC 2020 September 01.

Williams et al.

Page 10

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

[10]. Männistö T, Mendola P, Grewal J, Xie Y, Chen Z, Laughon SK, Thyroid diseases and adverse
pregnancy outcomes in a contemporary US cohort, J. Clin. Endocrinol. Metab. 98 (2013) 2725–
2733. [PubMed: 23744409]
[11]. Persson M, Pasupathy D, Hanson U, Norman M, Birth size distribution in 3,705 infants born to
mothers with type 1 diabetes: a population-based study, Diabetes Care 34 (2011) 1145–1149.
[PubMed: 21430084]
[12]. Lepercq J, Coste J, Theau A, Dubois-Laforgue D, Timsit J, Factors associated with preterm
delivery in women with type 1 diabetes, A cohort study 27 (2004) 2824–2828.
[13]. Cundy T, Slee F, Gamble G, Neale L, Hypertensive disorders of pregnancy in women with Type 1
and Type 2 diabetes, Diabet. Med. : a journal of the British Diabetic Association 19 (2002) 482–
489.
[14]. Hanson UI, Persson B, Outcome of pregnancies complicated by type 1 insulin-dependent
diabetes in Sweden: acute pregnancy complications, neonatal mortality and morbidity, Am. J.
Perinatol. 10 (1993) 330–333. [PubMed: 8397576]
[15]. Kim H-S, Jang H-J, Park J-E, Kim M-Y, Ko S-Y, Kim S-H, Maternal and neonatal outcomes in
Korean women with type 1 and type 2 diabetes, Diabetes & Metabolism Journal 39 (2015) 316–
320. [PubMed: 26301193]
[16]. Barnabe C, Faris PD, Quan H, Canadian pregnancy outcomes in rheumatoid arthritis and
systemic lupus erythematosus, International Journal of Rheumatology 2011 (2011) 345727.
[PubMed: 22028718]
[17]. Bundhun PK, Soogund MZ, Huang F, Impact of systemic lupus erythematosus on maternal and
fetal outcomes following pregnancy: a meta-analysis of studies published between years
2001-2016, J. Autoimmun. 79 (2017) 17–27. [PubMed: 28256367]
[18]. Barbhaiya M, Bermas BL, Evaluation and management of systemic lupus erythematosus and
rheumatoid arthritis during pregnancy, Clin. Immunol. 149 (2013) 225–235. [PubMed:
23773975]
[19]. Phansenee S, Sekararithi R, Jatavan P, Tongsong T, Pregnancy outcomes among women with
systemic lupus erythematosus: a retrospective cohort study from Thailand, Lupus (2017)
961203317721353.
[20]. Simard JF, Arkema EV, Nguyen C, Svenungsson E, Wikstrom AK, Palmsten K, et al., Earlyonset preeclampsia in lupus pregnancy, Paediatr. Perinat. Epidemiol. 31 (2017) 29–36. [PubMed:
27943386]
[21]. Bharti B, Lee SJ, Lindsay SP, Wingard DL, Jones KL, Lemus H, et al., Disease severity and
pregnancy outcomes in women with rheumatoid arthritis: results from the organization of
teratology information specialists autoimmune diseases in pregnancy project, J. Rheumatol. 42
(2015) 1376–1382. [PubMed: 25877497]
[22]. Wallenius M, Salvesen KÅ, Daltveit AK, Skomsvoll JF, Rheumatoid arthritis and outcomes in
first and subsequent births based on data from a national birth registry, Acta Obstet. Gynecol.
Scand. 93 (2014) 302–307. [PubMed: 24359405]
[23]. Spinillo A, Beneventi F, Locatelli E, Ramoni V, Caporali R, Alpini C, et al., The impact of
unrecognized autoimmune rheumatic diseases on the incidence of preeclampsia and fetal growth
restriction: a longitudinal cohort study, BMC Pregnancy Childbirth 16 (2016) 313. [PubMed:
27756248]
[24]. Konecna B, Laukova L, Vlkova B, Immune activation by nucleic acids: a role in pregnancy
complications, Scand. J. Immunol. 87 (2018) el2651.
[25]. Yalcin Serenat E, Yalcin Y, Yavuz A, Akkurt Mehmet O, Sezik M, Maternal and perinatal
outcomes in pregnancies with multiple sclerosis: a case-control study, J. Perinat. Med. (2017)
455. [PubMed: 27124670]
[26]. van der Kop ML, Pearce MS, Dahlgren L, Synnes A, Sadovnick D, Sayao A-L, et al., Neonatal
and delivery outcomes in women with multiple sclerosis, Ann. Neurol. 70 (2011) 41–50.
[PubMed: 21710652]
[27]. Chen YH, Lin HL, Lin HC, Does multiple sclerosis increase risk of adverse pregnancy
outcomes? A population-based study, Multiple Sclerosis Journal 15 (2009) 606–612. [PubMed:
19318510]

J Autoimmun. Author manuscript; available in PMC 2020 September 01.

Williams et al.

Page 11

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

[28]. Dahl J, Myhr K-M, Daltveit AK, Hoff JM, Gilhus NE, Pregnancy, delivery, and birth outcome in
women with multiple sclerosis, Neurology 65 (2005) 1961–1963. [PubMed: 16380620]
[29]. Goldacre A, Pakpoor J, Goldacre M, Perinatal characteristics and obstetric complications in
mothers with multiple sclerosis: record-linkage study, Multiple Sclerosis and Related Disorders
12 (2017) 4–8. [PubMed: 28283105]
[30]. Mueller BA, Zhang J, Critchlow CW, Birth outcomes and need for hospitalization after delivery
among women with multiple sclerosis, Am. J. Obstet. Gynecol. 186 (2002) 446–452. [PubMed:
11904605]
[31]. Nørgaard M, Larsson H, Pedersen L, Granath F, Askling J, Kieler H, et al., Rheumatoid arthritis
and birth outcomes: a Danish and Swedish nationwide prevalence study, J. Intern. Med. 268
(2010) 329–337. [PubMed: 20456595]
[32]. Lin H-C, Chen S-F, Lin H-C, Chen Y-H, Increased risk of adverse pregnancy outcomes in women
with rheumatoid arthritis: a nationwide population-based study, Ann. Rheum. Dis. 69 (2010)
715–717. [PubMed: 19406733]
[33]. Chen JS, Ford JB, Roberts CL, Simpson JM, March LM, Pregnancy outcomes in women with
juvenile idiopathic arthritis: a population-based study, Rheumatology 52 (2013) 1119–1125.
[PubMed: 23382363]
[34]. Mohamed MA, Goldman C, El-Dib M, Aly H, Maternal juvenile rheumatoid arthritis may be
associated with preterm birth but not poor fetal growth, J. Perinatol. 36 (2016) 268–271.
[PubMed: 26675002]
[35]. Gonzalez-Gonzalez NL, Ramirez O, Mozas J, Melchor J, Armas H, Garcia-Hernandez JA, et al.,
Factors influencing pregnancy outcome in women with type 2 versus type 1 diabetes mellitus,
Acta Obstet. Gynecol. Scand. 87 (2008) 43–49. [PubMed: 18158626]
[36]. Murphy HR, Steel SA, Roland JM, Morris D, Ball V, Campbell PJ, et al., Obstetric and perinatal
outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic
control, obesity and social disadvantage, Diabet. Med. : a journal of the British Diabetic
Association 28 (2011) 1060–1067.
[37]. Owens LA, Sedar J, Carmody L, Dunne F, Comparing type 1 and type 2 diabetes in pregnancysimilar conditions or is a separate approach required? BMC Pregnancy Childbirth 15 (2015) 69.
[PubMed: 25885892]
[38]. Yves J, Valerie V, Katrien VH, Guy M, Birth weight in type 1 diabetic pregnancy, 2010
Obstetrics and Gynecology International, 2010, p. 397623. [PubMed: 21234396]
[39]. Oron G, Yogev Y, Shcolnick S, Hod M, Fraser G, Wiznitzer A, et al., Inflammatory bowel
disease: risk factors for adverse pregnancy outcome and the impact of maternal weight gain, J.
Matern. Fetal Neonatal Med. 25 (2012) 2256–2260. [PubMed: 22524421]
[40]. Langen ES, Chakravarty EF, Liaquat M, El-Sayed YY, Druzin ML, High rate of preterm birth in
pregnancies complicated by rheumatoid arthritis, Am. J. Perinatol. 31 (2014) 009–014.
[41]. Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic
pregnancies: a large, population-based study, Diabetes Care 32 (2009) 2005–2009. [PubMed:
19675195]
[42]. Kelly VM, Nelson LM, Chakravarty EF, Obstetric outcomes in women with multiple sclerosis
and epilepsy, Neurology 73 (2009) 1831–1836. [PubMed: 19923552]
[43]. Getahun D, Fassett MJ, Longstreth GF, Koebnick C, Langer-Gould AM, Strickland D, et al.,
Association between maternal inflammatory bowel disease and adverse perinatal outcomes, J.
Perinatol. 34 (2014) 435–440. [PubMed: 24651735]
[44]. Evers IM, de Valk HW, Visser GHA, Risk of complications of pregnancy in women with type 1
diabetes: nationwide prospective study in The Netherlands, BM J Br. Med. J. (Clin. Res. Ed.) 328
(2004) 915.
[45]. Hamed HO, Ahmed SR, Alzolibani A, Kamal MM, Mostafa MS, Gamal RM, et al., Does
cutaneous lupus erythematosus have more favorable pregnancy outcomes than systemic disease?
A two-center study, Acta Obstet. Gynecol. Scand. 92 (2013) 934–942. [PubMed: 23621378]
[46]. Clowse ME, Jamison M, Myers E, James AH, A national study of the complications of lupus in
pregnancy, Am. J. Obstet. Gynecol. 199 (2008) 127.el–127.e6. [PubMed: 18456233]

J Autoimmun. Author manuscript; available in PMC 2020 September 01.

Williams et al.

Page 12

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

[47]. Nili F, McLeod L, O’Connell C, Sutton E, McMillan D, Maternal and neonatal outcomes in
pregnancies complicated by systemic lupus erythematosus: a population-based study, J. Obstet.
Gynaecol. Can. 35 (2013) 323–328. [PubMed: 23660039]
[48]. Wallenius M, Salvesen KA, Daltveit AK, Skomsvoll JF, Systemic lupus erythematosus and
outcomes in first and subsequent births based on data from a national birth registry, Arthritis Care
Res. 66 (2014) 1718–1724.
[49]. Broms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H, Complications from
inflammatory bowel disease during pregnancy and delivery, Clin. Gastroenterol. Hepatol. 10
(2012) 1246–1252. [PubMed: 22922307]
[50]. Hatch Q, Champagne BJ, Maykel JA, Davis BR, Johnson EK, Bleier JS, et al., Crohn’s disease
and pregnancy: the impact of perianal disease on delivery methods and complications, Dis. Colon
Rectum 57 (2014) 174–178. [PubMed: 24401878]
[51]. Ilnyckyji A, Blanchard JF, Rawsthorne P, Bernstein CN, Perianal Crohn’s disease and pregnancy:
role of the mode of delivery, Am. J. Gastroenterol. 94 (1999) 3274–3278. [PubMed: 10566729]
[52]. Stephansson O, Larsson H, Pedersen L, Kieler H, Granath F, Ludvigsson JF, et al., Crohn’s
disease is a risk factor for preterm birth, Clin. Gastroenterol. Hepatol. 8 (2010) 509–515.
[PubMed: 20202483]
[53]. Skomsvoll JF, Ostensen M, Irgens LM, Baste V, Pregnancy complications and delivery practice in
women with connective tissue disease and inflammatory rheumatic disease in Norway, Acta
Obstet. Gynecol. Scand. 79 (2000) 490–495. [PubMed: 10857874]
[54]. Atta DS, Girbash EF, Abdelwahab SM, Abdeldayem HM, Tharwat I, Ghonaim R, Maternal
cytokines and disease severity influence pregnancy outcomes in women with rheumatoid
arthritis, J. Matern. Fetal Neonatal Med. 29 (2016) 3358–3363. [PubMed: 26629845]
[55]. Dahl J, Myhr K-M, Daltveit AK, Gilhus NE, Pregnancy, delivery and birth outcome in different
stages of maternal multiple sclerosis, J. Neurol. 255 (2008)623–627. [PubMed: 18283397]
[56]. Vanya M, Nyari T, Bencsik K, Bartfai G, Pregnancy and perinatal outcomes among women with
multiple sclerosis: a retrospective case-controlled study in South Hungary, J. Matern. Fetal
Neonatal Med. 27 (2014) 577–581. [PubMed: 23865760]
[57]. Lateef A, Petri M, Managing lupus patients during pregnancy, Best Pract. Res. Clin. Rheumatol.
27 (2013) 435–447. [PubMed: 24238698]
[58]. Broms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H, Birth outcomes in women
with inflammatory bowel disease: effects of disease activity and drug exposure, Inflamm. Bowel
Dis. 20 (2014) 1091–1098. [PubMed: 24810137]
[59]. O’Toole A, Nwanne O, Tomlinson T, Inflammatory bowel disease increases risk of adverse
pregnancy outcomes: a meta-analysis, Dig. Dis. Sci. 60 (2015) 2750–2761. [PubMed: 26070523]
[60]. Davutoglu EA, Ozel A, Yilmaz N, Madazli R, Pregnancy Outcome in 162 Women with
Rheumatic Diseases: Experience of a University Hospital in Turkey, Archives of Gynecology and
Obstetrics, 2017.
[61]. Vargas R, Repke JT, Ural SH, Type 1 diabetes mellitus and pregnancy, Reviews in obstetrics &
gynecology 3 (2010) 92–100. [PubMed: 21364860]
[62]. Buyon JP, Systemic lupus erythematosus, in: Klippel JH, Stone JH, Crofford LJ, White PH
(Eds.), Primer on the Rheumatic Diseases, Springer New York, New York, NY, 2008, pp. 303–
338.
[63]. Baumgart DC, Sandborn WJ, Inflammatory bowel disease: clinical aspects and established and
evolving therapies, The Lancet 369 (2007) 1641–1657.
[64]. Hollenbach JA, Oksenberg JR, The immunogenetics of multiple sclerosis: a comprehensive
review, J. Autoimmun. 64 (2015) 13–25. [PubMed: 26142251]
[65]. Heidari B, Rheumatoid Arthritis: early diagnosis and treatment outcomes, Caspian Journal of
Internal Medicine 2 (2011) 161–170. [PubMed: 24024009]
[66]. Zhang J, Troendle J, Reddy UM, Laughon SK, Branch DW, Burkman R, et al., Contemporary
cesarean delivery practice in the United States, Am. J. Obstet. Gynecol. 203 (2010) 326 el-.el0.
[PubMed: 20708166]

J Autoimmun. Author manuscript; available in PMC 2020 September 01.

Williams et al.

Page 13

Author Manuscript
Author Manuscript
Author Manuscript

[67]. Yasmeen S, Romano PS, Schembri ME, Keyzer JM, Gilbert WM, Accuracy of obstetric
diagnoses and procedures in hospital discharge data, Am. J. Obstet. Gynecol. 194 (2006) 992–
1001. [PubMed: 16580288]
[68]. Goff SL, Pekow PS, Markenson G, Knee A, Chasan-Taber L, Lindenauer PK, Validity of using
ICD-9-CM codes to identify selected categories of obstetric complications, procedures and comorbidities, Paediatr. Perinat. Epidemiol. 26 (2012) 421–429. [PubMed: 22882786]
[69]. Rothman KJ, No adjustments are needed for multiple comparisons, Epidemiology 1 (1990) 43–
46. [PubMed: 2081237]
[70]. Engle WA, West KW, Hocutt GA, Pallotto EK, Haney B, Keith RJ, et al., Adult outcomes after
newborn respiratory failure treated with extracorporeal membrane oxygenation*, Pediatr. Crit.
Care Med. 18 (2017) 73–79. [PubMed: 27811529]
[71]. Boylan J, Alderdice FA, McGowan JE, Craig S, Perra O, Jenkins J, Behavioural outcomes at 3
years of age among late preterm infants admitted to neonatal intensive care: a cohort study, Arch.
Dis. Child. Fetal Neonatal Ed. 99 (2014) F359–F365. [PubMed: 24812103]
[72]. Amador-Patarroyo MJ, Rodriguez-Rodriguez A, Montoya-Ortiz G, How does age at onset
influence the outcome of autoimmune diseases? Autoimmune Dis. 2012 (2012) 251730.
[PubMed: 22195277]
[73]. Feldman AZ, Brown FM, Management of type 1 diabetes in pregnancy, Curr. Diabetes Rep. 16
(2016) 76.
[74]. Krause ML, Makol A, Management of rheumatoid arthritis during pregnancy: challenges and
solutions, Open Access Rheumatol. Res. Rev. 8 (2016) 23–36.
[75]. Partlett R, Roussou E, The treatment of rheumatoid arthritis during pregnancy, Rheumatol. Int. 31
(2011) 445–449. [PubMed: 21120498]
[76]. Coyle PK, Management of women with multiple sclerosis through pregnancy and after childbirth,
Therapeutic Advances in Neurological Disorders 9 (2016) 198–210. [PubMed: 27134675]
[77]. Stanhope TJ, White WM, Moder KG, Smyth A, Garovic VD, Obstetric nephrology: lupus and
lupus nephritis in pregnancy, Clin. J. Am. Soc. Nephrol. : CJASN 7 (2012) 2089–2099. [PubMed:
22879437]
[78]. Cimpoca BA, Nedelea F, Furtuna M, Peltecu G, Panaitescu AM, Managing Crohn’s disease
during pregnancy, Masdica 11 (2016) 221–226.
[79]. N. C. C. f. W. s. a. C. s. H. (UK, Diabetes in Pregnancy: Management of Diabetes and its
Complications from Preconception to the Postnatal Period, National Institute for Health and Care
Excellence, London, 2015.
[80]. Feldman AZ, Brown FM, Management of type 1 diabetes in pregnancy, Curr. Diabetes Rep. 16
(2016) 76.

Author Manuscript
J Autoimmun. Author manuscript; available in PMC 2020 September 01.

a

Author Manuscript

Author Manuscript

Author Manuscript
p < 0.01

168.5 (34439)

108.7 (22233)

p < 0.01

Hispanic

Other

p = 0.70

280.4 (57304

224.2 (45826

149.1 (30472)

p < 0.01

25-29

30-34

> =35

J Autoimmun. Author manuscript; available in PMC 2020 September 01.
p < 0.01

125.1 (25578)

p < 0.01

Other

p < 0.01

318.8 (65171)

p < 0.01

West

p-values assessed using fisher’s exact test.

2.2 (147)

102.3 (20919)

Midwest

3.1 (65)

2.9 (228)

388.1 (79336)

South

1.7 (67)

190.6 (38958)

Northeast

Region

0.9 (27)

303.3 (61982)

2.9 (181)

571.6 (116823)

Public

2.5 (299)

2.6 (121)

2.4 (136)

Private

Insurance

2.5 (76)

253.6 (51829)

20-24

2.4 (127)

92.7 (18953)

2.5 (47)

2.0 (70)

< 20

Age

0.1 (33)

208.3 (42576)

Black

2.9 (124)

514.4 (105136)

2.6 (280)

Type I Diabetes 2.4
(507)

p < 0.01

0.7 (43)

0.9 (18)

1.4 (115)

0.7 (26)

p < 0.01

0.1 (2)

1.0 (65)

1.1 (135)

p < 0.01

1.0 (31)

1.4 (64)

0.9 (52)

0.9 (49)

0.3 (6)

p = 0.16

< .01 (16)

0.9 (30)

1.3 (57)

0.9 (99)

Systemic Lupus
Erythematosus 0.9 (202)

Autoimmune Disease Rate of disease per 1000 (n)

White

Race

Women without
autoimmune disease (N =
204384)

p < 0.01

0.5 (36)

0.9 (18)

0.8 (61)

1.4 (54)

p < 0.01

0.3 (8)

0.5 (34)

1.1 (127)

p < 0.01

0.9 (27)

1.1 (52)

1.0 (56)

0.5 (25)

0.5 (9)

p < 0.01

< 0.1 (4)

< 0.1 (1)

0.5 (20)

1.4 (144)

Crohn’s Disease 0.8
(169)

p = 0.84

0.7 (44)

0.7 (15)

0.7 (55)

0.8 (32)

p = 0.02

0.5 (12)

0.5 (32)

0.9 (102)

p < 0.01

1.3 (40)

1.2 (55)

0.6 (34)

0.3 (15)

0.1 (2)

p < 0.01

< 0.1 (6)

0.2 (8)

0.7 (28)

1.0 (104)

Multiple Sclerosis 0.7
(146)

p = 0.06

1.4 (28)

0.4 (9)

0.7 (57)

0.7 (29)

p = 0.19

0.3 (8)

0.6 (36)

0.7 (79)

p < 0.01

1.3 (39)

0.8 (36)

0.4 (22)

0.3 (14)

0.6 (12)

p = 0.02

< 0.1 (12)

0.3 (10)

0.5 (20)

0.8 (81)

Rheumatoid Arthritis 0.5
(123)

Demographic characteristics of women without autoimmune disease and rate per 1000 (and frequency) of autoimmune disease by demographic variables
from the Consortium of Safe Labor, 2002–2008 (n = 205521).

Author Manuscript

Table 1
Williams et al.
Page 14

Author Manuscript
Rates per 1000 are specific for each demographic category (rate = (outcome n/autoimmune disease N)*1000).

Author Manuscript

a

Williams et al.
Page 15

Author Manuscript

Author Manuscript

J Autoimmun. Author manuscript; available in PMC 2020 September 01.

Author Manuscript

Author Manuscript

a

Author Manuscript
b
b
b
b

b
b

b
b

b

145.9 (74)
159.7 (81)
408.2 (207)

b

b

111.0 (22701)
78.4 (16038)
17.8 (3650)
46.4 (9498)
115.4 (23593)
31.1 (6357)
109.3 (22350)
5.9 (1214)

Preterm Birth

Spontaneous

Indicated

Preeclampsia

NICU Admission

Neonatal Respiratory
Distress Syndrome

Small for Gestational
Age

Perinatal Mortality
13.8 (7)

65.0 (33)

b

130.1 (66)

248.5 (126)

426.0 (216)

195.3 (99)

b

19.8 (4)

b

178.2 (36)

b

113.8 (23)

282.1 (57)

138.6 (28)

103.9 (21)

232.7 (47)

376.2 (76)

J Autoimmun. Author manuscript; available in PMC 2020 September 01.
b

5.9 (1)

124.2 (21)

47.3 (8)

b
195.3 (33)

b

82.8 (14)

b

29.5 (5)

b

130.1 (22)

195.3 (33)

59.2 (10)

118.3 (20)

b

183.4 (31)

b

360.9 (61)

Crohn’s Disease (n =
169)

b

0 (0)

75.3 (11)

34.0 (5)

164.3 (24)

61.6 (9)

27.3 (4)

b
143.8 (21)

191.7 (28)

68.5 (10)

123.3 (18)

b

232.9 (34)

b

424.7 (62)

Multiple Sclerosis (n
= 146)

b

b

b
0 (0)

170.7 (21)

48.7 (6)

195.1 (24)

81.3 (10)

16.2 (2)

b
154.4 (19)

178.8 (22)

48.8 (6)

130.1 (16)

b
211.4 (26)

b
390.2 (48)

Rheumatoid Arthritis (n
= 123)

p < 0.05 indicates rates among women with autoimmune disease different than rates among women without autoimmune disease. P-values obtain using generalized estimating equations to account for
women who had more than one pregnancy in the study.

b

Rates per 1000 are specific for each autoimmune disease category (rate = (outcome n/autoimmune disease N)*1000).

a

b

84.2 (17)

b

205.1 (104)

71.9 (14692)

After induced labor

123.8 (25)

b

93.0 (19016)

After spontaneous labor

b

183.2 (37)

b

270.2 (137)

113.6 (23218)

Prelabor cesarean

670.6 (340)

278.5 (56926)

Cesarean Delivery
391.1 (79)

Systemic Lupus
Erythematosus (n = 202)

b

Type I Diabetes (n =
507)

Autoimmune Disease

b

Women without
autoimmune disease (n =
204384)

Rate per 1000 (and frequency) of obstetric and neonatal outcomes for singleton pregnancies from the Consortium of Safe Labor 2002–2008 (n =
205521).

Author Manuscript

Table 2
Williams et al.
Page 16

Author Manuscript

Author Manuscript

Author Manuscript
2.90 (2.42, 3.48)*

3.52 (3.17, 3.91)*

Reference

1.13 (1.00, 1.28)*

1.25 (1.16, 1.35)*

Reference

NICU

–

1.07 (0.93, 1.23)

1.62 (0.81, 3.23)

1.26 (0.82, 1.93)

1.03 (0.89, 1.20)

1.68 (1.12, 2.53)*

1.79 (0.76, 4.20)

1.84 (1.37, 2.49)*

1.36 (0.90, 2.05)

0.91 (0.50, 1.64)

1.05 (1.00, 1.11)*

1.31 (1.08, 1.60)*

Crohn’s Disease (n =
169) RR (95% CI)

–

1.04 (0.89, 1.21)

1.08 (0.45, 2.58)

0.76 (0.42, 1.38)

1.02 (0.87, 1.19)

1.73 (1.14, 2.64) *

1.48 (0.57, 3.81)

1.67 (1.20, 2.30) *

1.23 (0.80, 1.87)

0.96 (0.53, 1.74)

1.07 (1.02, 1.13) *

1.33 (1.11, 1.61) *

Multiple Sclerosis (n =
146) RR (95% CI)

–

1.06 (0.90, 1.25)

1.44 (0.65, 3.21)

1.66 (1.08, 2.55) *

1.03 (0.87, 1.23)

1.87 (1.23, 2.86) *

0.80 (0.20, 3.10)

1.42 (0.97, 2.07)

1.33 (0.85, 2.09)

0.64 (0.29, 1.43)

1.05 (0.99, 1.11)

1.18 (0.94, 1.49)

Rheumatoid Arthritis (n
= 123) RR (95% CI)

J Autoimmun. Author manuscript; available in PMC 2020 September 01.

p < .05 indicates rates among women with autoimmune disease different than rates among women without autoimmune disease.

*

Models adjusted for maternal age, maternal race/ethnicity, preconception body mass index, health insurance, marital status, smoking in pregnancy, alcohol use in pregnancy, other chronic diseases, and
census region.;

Perinatal
Mortalityrowhead

–

2.99 (1.99, 4.51)*

3.62 (2.84, 4.62)*

Reference

Respiratory Distress
Syndrome

2.35 (1.12, 4.91)*

1.68 (1.21, 2.32)*

0.61 (0.43, 0.86)*

Reference

Small for Gestational Age

Reference

1.09 (0.96, 1.24)

1.11 (1.02, 1.20)*

Reference

Preeclampsia

Admission

2.62 (2.01, 3.40)*

3.06 (2.61, 3.58)*

Reference

4.59 (3.05, 6.91)*

Spontaneous

7.12 (5.73, 8.84)*

Reference

Indicated

Preterm

1.23 (0.86, 1.77)

1.90 (1.61, 2.26)*

Reference

1.05 (0.66, 1.66)

After Spontaneous

2.58 (2.17, 3.06) *

Reference

1.03 (0.99, 1.08)

After Induction

1.13 (1.09, 1.16)*

Reference

1.21 (1.02, 1.44)*

2.16 (2.02, 2.32)*

Reference

Prelabor

Cesarean

Systemic Lupus
Erythematosus (n = 202) RR
(95% CI)

Type I Diabetes (n =
507) RR (95% CI)

Women without
autoimmune
disease (n =
204384)
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Failed VBAC

Shoulder dystocia

History of shoulder dystocia

0 (0)

0 (0)

0 (0)

1.9 (1)

0 (0)

1.9 (1)

1.9 (1)

1.9 (1)

3.8 (2)

0 (0)

9.8 (5)

c

19.7 (10)

c

19.7 (10)

c

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

4.9 (1)

0 (0)

4.9 (1)

0 (0)

0 (0)

c

9.9 (2)

14.8 (3)

0 (0)

19.8 (4)

c

34.6 (7)
4.9 (1)

47.3 (24)

c

113.8 (23)

c

44.5 (9)

207.9 (42)

Systemic Lupus
Erythematosus (n = 202)

19.7 (10)

90.7 (46)

c

c

78.9 (40)

149.9 (76)

c

400.3 (203)

c

Type I Diabetes (n =
507)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

5.9 (1)

5.9 (1)

5.9 (1)

0 (0)

c

11.8 (2)

11.8 (2)

5.9 (1)

17.7 (3)

c

11.8 (2)

29.5 (5)

c

88.7 (15)

177.5 (30)

NRFHRT, non-reassuring fetal heart rate tracing.

c
p < 0.05 Indicates rate among women with autoimmune disease different than rate among women without autoimmune disease.

b

Categories for the indicated precursors are not mutually exclusive as multiple obstetric or fetal conditions were included in the same pregnancy.

a

37.7 (7714)

b

NRFHRT

65.5 (13394)

164.9 (33708)

Failure to progress

Intrapartum Cesarean Delivery

Women without
autoimmune disease (n =
204,384)
Crohn’s Disease (n
= 169)

Author Manuscript

Rate per l,000 (and frequency) of intrapartum cesarean delivery: overall and by indication.

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

6.8 (1)

0 (0)

6.8 (1)

0 (0)

0 (0)

0 (0)

20.5 (3)

0 (0)

c

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

8.1 (1)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

16.2 (2)

0 (0)

8.1 (1)

8.1 (1)

c

27.3 (4)

48.7 (6)

40.6 (5)

c
48.7 (6)

178.8 (22)

Rheumatoid Arthritis
(n = 123)

41.0 (6)

c

6.8 (1)

c

95.8 (14)

191.7 (28)

Multiple Sclerosis (n
= 146)

Author Manuscript
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Author Manuscript

Author Manuscript
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d

1.51 (310)
1.25 (256)
1.23 (252)
1.15 (237)

Stillbirth

Pregestational diabetes

Gestational Hypertension

Maternal Fever

0.94 (194)
0.81 (167)
0.67 (138)
0.27 (57)
0.25 (53)
0.20 (42)
0.20 (41)
0.13 (28)
0.12 (26)

Chronic hypertension

Abruption

Prior uterine scar

Unspecified HTN

Chorioamnionitis

Fetal macrosomia

Vaginal bleeding

Previa

Eclampsia

Admission for fetal reason

1.12 (229)

1.68 (345)

Superimposed Preeclampsia

e

1.89 (388)

2.16 (443)

2.64 (540)

Gestational diabetes

Fetal condition

Fetal anomaly

2.89 (592)

2.98 (611)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1.97 (1)*
0 (0)

0 (0)

1.97 (1)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

4.95 (1)*

1.97 (1)*

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

5.91 (1)

0 (0)

5.91 (1)

11.83 (2)

0 (0)

0 (0)

5.91 (1)

11.83 (2)

17.75 (3)*

0 (0)

0 (0)

1.97 (1)

9.90 (2)

9.90 (2)

15.77 (8)*
1.97 (1)

4.95 (1)

4.95 (1)

9.90 (2)

9.90 (2)

3.94 (2)

7.88 (4)

11.83 (6)

145.9 (74)

4.95 (1)

4.95 (1)*

23.66 (12)*
3.94 (2)

4.95 (1)

0 (0)

14.85 (3)*

24.75 (5)*

27.61 (14)*
7.88 (4)

24.75 (5)

14.85 (3)

27.61 (14)*
27.61 (14)*

49.50 (10)

43.39 (22)*

17.75 (3)

29.5 (5)*

p < 0.05 Indicates rate among women with autoimmune disease different than rate among women without autoimmune disease.

*

c

History of pregnancy condition

Admission for maternal reason

Maternal Condition

b

29.70 (6)*

47.33 (24)*

6.59 (1348)

Preeclampsia (all)
4.95 (1012)

103.9 (21)*

145.9 (74)*

17.8 (3650)

Indicated Preterm Delivery

b

Systemic Lupus
Erythematosus (n = 202)

Type I Diabetes (n =
507)

Women without
autoimmune disease (n =
204,384)

Crohn’s Disease (n
= 169)

Author Manuscript

Rate per l,000 (and frequency) of indicated PTB: overall and by indication.

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

6.84 (1)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

6.84 (1)

13.69 (2)

0 (0)

0 (0)

6.84 (1)

0 (0)

6.84 (1)

6.84 (1)

27.3 (4)

Multiple Sclerosis
(n = 146)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

8.13 (1)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

8.13 (1)

0 (0)

8.13 (1)

8.13 (1)

0 (0)

0 (0)

0 (0)

16.2 (2)

Rheumatoid Arthritis
(n = 123)

Author Manuscript
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Author Manuscript
Admission for fetal or maternal reason was included only if there was no other pregnancy condition.

e

Fetal conditions included intrauterine growth restriction and abnormal antenatal testing.

History of maternal or fetal condition included pregnancy complications in a previous pregnancy only.

d

c

Maternal conditions included maternal medical problems such as cardiac or renal disease.

b

Categories for the indicated precursors are not mutually exclusive as multiple obstetric or fetal conditions were included in the same pregnancy.

Author Manuscript

a
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